NEW YORK — A Wachovia Capital Markets analyst began coverage of the biotechnology sector Thursday, with drug candidates marking the difference between leading stocks and less promising ones.
NEW YORK — A Wachovia Capital Markets analyst began coverage of the biotechnology sector Thursday, with drug candidates marking the difference between leading stocks and less promising ones.
